CPBIO is proud to announce its ranking as the Global #2 in the "Top 20 Emerging Animal Health Companies" by PharmaShots. This recognition solidifies CPBIO’s leadership in the 2026 animal health landscape.

Leading a $172B Market Revolution

The global animal health market is set for massive expansion, projected to rise from $73 billion in 2025 to over $172 billion by 2035 (9% CAGR). As the industry shifts toward targeted biologics and sustainable solutions, CPBIO is at the forefront of this growth.

Our ranking reflects the strength of CP Group’s integrated value chain and our "evidence-first" philosophy. By bridging the gap between laboratory research and farm-level success, we are delivering the affordable care and high-efficiency therapies that modern veterinary demands require.

Our Commitment

PharmaShots highlights that emerging leaders are gaining ground through innovation and strategic launches. At CPBIO, we remain dedicated to:

Next-Gen Biologics: Advancing vaccines and targeted therapies.

Global Access: Enhancing productivity tools for livestock and pets.

Sustainability: Ensuring a healthier world for animals and people alike.

We thank PharmaShots for recognizing the innovators setting the tone for the next decade.